Literature DB >> 14505153

Suppression of proliferative cholangitis in a rat model by local delivery of paclitaxel.

Seon-Mee Park1, Jae-Woon Choi, Seung-Taik Kim, Myung-Chan Cho, Ryo Hyen Sung, Lee-Chan Jang, Jin-Woo Park, Sum Ping Lee, Yong-Hyun Park.   

Abstract

BACKGROUND: Proliferative cholangitis (PC) leads to biliary stricture, which is the main cause of hepatolithiasis, recurrent cholangitis, and biliary cirrhosis. The aim of this study was to determine whether local delivery of paclitaxel, which inhibits cell proliferation by overstabilization of microtubules, prevents PC in a rat model.
METHODS: PC was induced by introducing a fine nylon thread into the bile duct in a rat. Paclitaxel (100 microl of 10, 100, and 1000 micromol/l) or solvent vehicle was administered into the bile duct for 15 min. One week after treatment, histopathologic examination and 5-bromodeoxyuridine (BrdU) labeling of the bile duct were performed.
RESULTS: In comparison with the control, the mean thickness of the bile duct was reduced by 29% in the 1000 micromol/l paclitaxel-treated group (2.61 +/- 0.31 microm vs 3.67 +/- 0.25 micro m, P << 0.05). The luminal area increased ( P << 0.0001) and the grade of epithelial-glandular proliferation was decreased ( P << 0.01) as the dose of paclitaxel increased. Ductal fibrosis and inflammatory cell infiltration were similar in both groups. The BrdU labeling index was significantly lower in the paclitaxel-treated group ( P << 0.05).
CONCLUSIONS: Local delivery of paclitaxel suppressed PC in a rat model by the inhibition of epithelial-glandular proliferation and may offer an effective therapeutic option for biliary stricture.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14505153     DOI: 10.1007/s00534-002-0804-9

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  5 in total

1.  Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts.

Authors:  Ho-Soon Choi; Christopher E Savard; Jae-Woon Choi; Rahul Kuver; Sum P Lee
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

Review 2.  Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.

Authors:  Fu Yu Li; Nan Sheng Cheng; Hui Mao; Li Sheng Jiang; Jing Qiu Cheng; Quan Sheng Li; Sanjay Munireddy
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

3.  Treatment of chronic proliferative cholangitis with c-myc shRNA.

Authors:  Fu-Yu Li; Nan-Sheng Cheng; Jing-Qiu Cheng; Hui Mao; Li-Sheng Jiang; Ning Li; Sheng He
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

4.  Effects of Paclitaxel-conjugated N-Succinyl-Hydroxyethyl Chitosan Film for Proliferative Cholangitis in Rabbit Biliary Stricture Model.

Authors:  Tao Wang; Hao Zou; Yun-Xia Liu; Xiao-Wen Zhang
Journal:  Chin Med J (Engl)       Date:  2018-03-20       Impact factor: 2.628

5.  Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits.

Authors:  Qin Yang; Zhenru Wu; Fei Liu; Junke Wang; Wenjie Ma; Haijie Hu; Fuyu Li; Qiuwei Pan
Journal:  Biomed Res Int       Date:  2018-07-24       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.